Development of method to evaluate anti-oxidative capability of Kampo in chronic kidney disease

Development of method to evaluate anti-oxidative capability of Kampo in chronic kidney disease - Anti-oxidative action of Kampo in chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000850

Enrollment

Registered

2007-11-01

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Treatment group: administration of Hochu-ekki-tou (2.5g x 3/day) for 2 or 4 weeks Control group: follow-up for 2-4 weeks without administration of Kampo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic kidney disease with serum creatinine level >=2.0mg/dl

Exclusion criteria

Exclusion criteria: patients taking other Kampo medication than Hochu-ekki-tou. patients who have experienced adverse effects of Kampo medication.

Design outcomes

Primary

Measure	Time frame
to evaluate the ability of Kampo to reduce oxidative stress with the use of oxidative/redox tiol compounds or monoclonal antibodies.	—

Countries

Japan

Contacts

Public ContactKOICHI HAYASHI

Department of Internal Medicine, School of Medicine, Keio University Division of Nephrology, Endocrinology and Metabolism

khayashi@sc.itc.keio.ac.jp03-5363-3796

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026